TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03138096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pb(PfCS@UIS4)-infected mosquitoes
Description: Pb(PfCS@UIS4)-infected mosquitoes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pb(PfCS@UIS4)-infected mosquitoes
Description: Pb(PfCS@UIS4)-infected mosquitoes
Study: NCT01821625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
Study: NCT02283996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.~Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:~http://www.brighamandwomens.org/Patients_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot Methylprednisolone
Description: 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot Methylprednisolone
Description: 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
Study: NCT03777592

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: erector spinae plane block
Description: local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces
Study: NCT00160732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic islet cells (human, U. Chicago)
Description: Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of islet cells
Description: Intraportal infusion of islet cell through the portal vein in the liver.
Study: NCT00182455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 25 - 400 mg/day x 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 - 400 mg/day x 12 weeks
Study: NCT01916681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Foley & Misoprostol
Description: A cervical foley combined with misoprostol will be used to induce the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol Alone
Description: Misoprostol will be used alone to induce the patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Foley Alone
Description: A cervical foley alone will be used to induce the patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Foley & Pitocin
Description: A cervical foley combined with pitocin will be used to induce the patient
Study: NCT04496193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block
Description: Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
Study: NCT03618173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV dexamethasone at the dose of 0,2mg/kg = 0,2mL/kg of a solution of 1mg/mL max 8mg
Study: NCT03868449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Question Prompt List
Description: Question prompt list
Study: NCT03138096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pb(PfCS@UIS4)-infected mosquitoes
Description: Pb(PfCS@UIS4)-infected mosquitoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge infection P. falciparum
Description: Challenge infection with bites of five infected Pf mosquitoes

Intervention type: OTHER
Group type: OTHER
Intervention: Challenge infection P. falciparum
Description: Challenge infection with bites of five infected Pf mosquitoes

Intervention type: OTHER
Group type: OTHER
Intervention: Challenge infection P. falciparum
Description: Challenge infection with bites of five infected Pf mosquitoes
Study: NCT04274894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel 1.62%
Description: AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
Study: NCT02044185

Intervention type: DRUG
Intervention: salvage chemotherapy, total body irradiation
Description: there are no direct interventions to our patients.

Intervention type: DRUG
Intervention: salvage chemotherapy, total body irradiation
Description: there are no direct interventions to our patients.
Study: NCT03943784

Intervention type: PROCEDURE
Intervention: Endoscopic Variceal Ligation
Description: Endoscopic varices ligation was performed with a six-shooter multiband ligator (Cook Medical, Limerick, Ireland) if medium to large varices or reddish spots, regardless of the grade of the varix, were observed. Each varix was ligated 1-2 cm above the gastro-esophageal junction, with 1 or 2 rubber bands and using no more than 5 rubber bands per session.
Study: NCT03618173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV saline serum at the dose of 0,2mL/kg maximum 8mL
Study: NCT02371317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Patients are randomized to an intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Education
Description: Patients are randomized to an intervention

Intervention type: OTHER
Group type: OTHER
Intervention: American Heart Association Recommended Self-Care
Description: All Patients receive AHA Recommended Self-Care
Study: NCT03943784

Intervention type: DRUG
Intervention: Non-Selective Beta-Blocking Agent
Description: Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
Study: NCT02744833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium (Lovenox®)
Study: NCT00975312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple combination cream
Description: The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05%
Description: Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
Study: NCT03118024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Solutions
Description: crystalloid restrictive anesthesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Catecholamines
Description: catecholamine restrictive anesthesia protocol
Study: NCT01936857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Maintenance Therapy
Description: Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
Study: NCT03115892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Green Tea With Aloe Vera mouthwash
Description: measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: chlorohexidine mouthwash take two times per day for one week
Study: NCT04475432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03, 0.25%
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TP-03 Vehicle
Description: Vehicle of TP-03 ophthalmic solution, administered twice a day
Study: NCT02371317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Heart Association Recommended Self-Care
Description: All Patients receive AHA Recommended Self-Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Heart Association Recommended Self-Care
Description: All Patients receive AHA Recommended Self-Care
Study: NCT04384042

Intervention type: OTHER
Intervention: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
Description: This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.

Intervention type: OTHER
Intervention: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
Description: This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
Study: NCT03290261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: 3 hypnosis sessions performed at 4 - 6 weeks apart
Study: NCT03795961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current electrical stimulation
Description: anodal tDCS of M1 for 20 minutes, at 2 mA for 5 sessions (day after day)
Study: NCT03701984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
Study: NCT00975910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
Study: NCT03795961

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current electrical stimulation
Description: anodal tDCS of M1 for 20 minutes, at 2 mA for 5 sessions (day after day)
Study: NCT00823147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Induction
Description: Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
Study: NCT04049162

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Plus Exercise (BB-EX)
Description: Pre-packaged blueberry powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blueberry Placebo Plus Exercise (P-EX)
Description: Pre-packaged placebo powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
Study: NCT04357067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual brackets
Description: A type of bracket that applied lingual surface of teeth.
Study: NCT00975910

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline arm: infused at the same rate as lidocaine
Study: NCT00406003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release tablet
Description: Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release tablet
Description: Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release tablet
Description: Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release tablet
Description: Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release tablet
Description: Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release tablet
Description: Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
Study: NCT01552590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04781738

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages~Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test.~SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items).~Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state).

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages~Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test.~SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items).~Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state).
Study: NCT00734630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebivolol
Description: Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
Study: NCT02034708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem®
Description: Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem®
Description: Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadovist®/Gadavist®
Description: Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadovist®/Gadavist®
Description: Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
Study: NCT01479387

Intervention type: DRUG
Intervention: [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Description: Patients who have received In-111 Zevalin.
Study: NCT03433989

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: telephone interview
Description: questionnaire PDEQ et IES-R
Study: NCT01925833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Both insertion and withdrawal
Description: inspection and polypectomy during both insertion and withdrawal of colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only withdrawal
Description: inspection and polypectomy during only withdrawal of colonoscopy
Study: NCT00733980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04263597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose
Description: 2FL powder will be provided to participants randomized to receive 2FL in packets. They will be instructed to drink this daily by adding the required amount to food or drink. It may also be mixed in standard feeds or mixed with water and administered by enteral tube, whenever applicable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose
Description: 2FL powder will be provided to participants randomized to receive 2FL in packets. They will be instructed to drink this daily by adding the required amount to food or drink. It may also be mixed in standard feeds or mixed with water and administered by enteral tube, whenever applicable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose
Description: 2FL powder will be provided to participants randomized to receive 2FL in packets. They will be instructed to drink this daily by adding the required amount to food or drink. It may also be mixed in standard feeds or mixed with water and administered by enteral tube, whenever applicable.
Study: NCT02693938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Follicular Euglycemic clamp
Description: Follicular Euglycemic clamp during follicular phase

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luteal Euglycemic clamp
Description: Luteal Euglycemic clamp during luteal phase